Latent tuberculosis screening for inflammatory bowel disease in tuberculosis endemic region remains porous and suboptimal: A multicentre study

doi:10.3748/wjg.v32.i4.114897

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 4

This Article

(44)

(96)

(0)

(20)

(1506)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastroenterol. Jan 28, 2026; 32(4): 114897
Published online Jan 28, 2026. doi: 10.3748/wjg.v32.i4.114897

Table 4 Predictors of active tuberculosis among inflammatory bowel disease patients on advanced therapy, n (%)/mean ± SD

	Active tuberculosis (n = 17)	No tuberculosis (n = 361)	P value
Age (years)	40.93 ± 15.60	36.76 ± 14.96	0.263
Gender, male	13 (76.5)	203 (56.2)	0.095
IBD type			0.761
CD	11 (64.7)	205 (56.8)
UC	6 (35.3)	152 (42.1)
Unclassified	0	4 (1.1)
Duration of disease (months)	60 (12-72)	48 (24-72)	0.379
TNFi	15 (88.2)	294 (81.4)	0.748
Infliximab	12	195
Adalimumab	3	99
Standard screening	4 (23.52)	73 (20.22)	1.000
Diligent	7 (41.17)	118 (32.68)	0.444
Immunodiagnostic			0.905
TST and IGRA	11 (64.70)	197 (54.57)
TST or IGRA	16 (94.11)	337 (93.35)
Neither	1 (5.88)	24 (6.64)
CT done	10 (58.82)	232 (64.26)	0.617
Combination immunosuppression	16 (94.11)	301 (83.37)	0.329
Steroids			0.673
Any dose	5 (29.41)	171 (47.36)
High dose	1 (5.88)	73 (20.22)
Presence of LTB	5 (29.41)	35 (9.69)	0.033

IBD: Inflammatory bowel disease; CD: Crohn’s disease; UC: Ulcerative colitis; TNFi: Tumor necrosis factor inhibitor; TST: Tuberculin skin test; IGRA: Interferon-gamma release assay; CT: Computed tomography; LTB: Latent tuberculosis.

Full Size Table

Citation: Jha DK, Prasad S, Valsan A, Mishra S, Nair P, Koshy AK, Singh S, Prasad AS, Shukla R, Ahamed R, Augustine P, Natarajan K, Peddi K, Kulkarni A, Bhatia S, Pachisia AV, Singh PK, Jena A, Gupta S, Jain S, Padmaprakash K, Kakadiya R, Kumar A, Shukla S, Dutta U, Hande V, Thareja S, Sharma V. Latent tuberculosis screening for inflammatory bowel disease in tuberculosis endemic region remains porous and suboptimal: A multicentre study. World J Gastroenterol 2026; 32(4): 114897
URL: https://www.wjgnet.com/1007-9327/full/v32/i4/114897.htm
DOI: https://dx.doi.org/10.3748/wjg.v32.i4.114897

Jha DK, Prasad S, Valsan A, Mishra S, Nair P, Koshy AK, Singh S, Prasad AS, Shukla R, Ahamed R, Augustine P, Natarajan K, Peddi K, Kulkarni A, Bhatia S, Pachisia AV, Singh PK, Jena A, Gupta S, Jain S, Padmaprakash K, Kakadiya R, Kumar A, Shukla S, Dutta U, Hande V, Thareja S, Sharma V. Latent tuberculosis screening for inflammatory bowel disease in tuberculosis endemic region remains porous and suboptimal: A multicentre study. World J Gastroenterol 2026; 32(4): 114897 [PMID: 41640875 DOI: 10.3748/wjg.v32.i4.114897]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.